ImExHS (ASX:IME) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IME ImExHS Ltd ASX:IME
50 GF Score
Price A$0.31
GF Value A$0.51
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is ImExHS Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of ImExHS is: High Risk: High uncertainty.

ImExHS  (ASX:IME) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

ImExHS Risk Assessment Related Terms

ASX:IME vs TMO, DHR, IDXX: Risk Assessment Comparison

For the Diagnostics & Research subindustry, ImExHS's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImExHS Risk Assessment vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ImExHS's Risk Assessment distribution charts can be found below:

* The bar in red indicates where ImExHS's Risk Assessment falls into.


ASX:IME
50GF Score
ImExHS Ltd ASX:IME
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ImExHS (ASX:IME) Overvalued in 2026?

Based on GuruFocus' analysis, ImExHS stock appears to be undervalued. The current stock price of A$0.31 is trading 39.2% below its estimated GF Value™ of A$0.51. GuruFocus considers ImExHS to be Possible Value Trap.

Key valuation signals for ASX:IME:

  • Risk Assessment:
  • GF Value™: A$0.51 vs. price of A$0.31 (39.2% below fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the ASX:IME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImExHS Business Description

Address 32 Martin Place, Level 7, Sydney, NSW, AUS, 2020
ImExHS Ltd is a healthcare technology company engaged in the provision of medical imaging software and radiology services. The company develops and delivers enterprise imaging solutions, including radiology information systems and picture archiving and communication systems, as well as provides diagnostic imaging and teleradiology services to healthcare institutions. The company operates through two reportable segments: Software, which focuses on the development and sale of imaging systems and platforms, and Radiology Services, which provides diagnostic and teleradiology services to hospitals and medical facilities. It generates the majority of its revenue from the Radiology segment.
50GF Score

Get the complete analysis for ASX:IME

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.31
Price
A$0.51
GF Value